EFG
CTKB icon

Everhart Financial Group’s Cytek Biosciences CTKB Stock Holding History

Everhart Financial Group’s Portfolio CTKB Stock Details CTKB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$57.4K Hold
12,962
– – ﹤0.01% 475
2026
Q1 		$56.6K Hold
12,962
– – ﹤0.01% 456
2025
Q4 		$65.5K Hold
12,962
– – 0.01% 415
2025
Q3 		$45K Hold
12,962
– – ﹤0.01% 388
2025
Q2 		$44.1K Buy
+12,962
New +$43.2K 0.01% 339

Other funds holding CTKB

YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
NAM
NorthCrest Asset Manangement Plymouth, Minnesota $3.89B AUM 40.33% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
TWD
True Wealth Design Akron, Ohio $420M AUM 22.7% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.12B AUM 34.21% 1-Year Est. Return
DCM
Davis Capital Management Jacksonville, Florida $169M AUM 22.99% 1-Year Est. Return

Everhart Financial Group's CTKB Position: Q2 2026 in Review

Everhart Financial Group held its Cytek Biosciences (CTKB) position steady in Q2 2026 at 12,962 shares worth $57.4K. The position accounts for ﹤0.01% of the portfolio, ranked #475.

Everhart Financial Group first reported a position in CTKB in Q2 2025 and has held it in 5 quarters since. The position peaked at $65.5K in Q4 2025. 8 funds tracked by Wall St. Rank hold CTKB as of Q2 2026.

  • Everhart Financial Group held 12,962 shares of Cytek Biosciences worth $57.4K as of Q2 2026.
  • Everhart Financial Group left its Cytek Biosciences share count unchanged in Q2 2026.
  • Cytek Biosciences made up ﹤0.01% of Everhart Financial Group's portfolio in Q2 2026, its #475 holding.
  • Everhart Financial Group first reported a position in Cytek Biosciences in Q2 2025 and has held it in 5 quarters since.
  • Everhart Financial Group's Cytek Biosciences position peaked at $65.5K in Q4 2025.
  • 8 funds tracked by Wall St. Rank held Cytek Biosciences as of Q2 2026.

Based on Everhart Financial Group's 13F filing for Q2 2026, filed 9 Jul 2026.